News

Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...

This is the 17th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...

THE INSTAGRAM POST, precision-guided by sex and age, had zeroed in on its target. Yuchen Tu is a conser­vatory-trained viola...

This is the 16th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring...

DNA strand
By Walt Bogdanich and Carson Kessler, The New York Times | 10.23.2024

By 2021, nearly 2,000 volunteers had answered the call to test an experimental Alzheimer’s drug known as BAN2401. For the...

CRISPR editing on DNA strand
By Kevin Davies, Genetic Engineering and Biotechnology News | 10.22.2024

In an extraordinary 6,000-word guest editorial in the October 2024 issue of The CRISPR Journal (a sister journal of GEN, ...

ivf
By Ruth Retassie, PET | 10.21.2024

Former IVF patients in the USA have filed class action lawsuits against several companies for misleading them about the efficacy...

sickle cell
By Gina Kolata, The New York Times | 10.21.2024

Kendric Cromer, 12, left Children’s National Hospital in a wheelchair on Wednesday, wearing a T-shirt and cap printed with designs...

dna
By Nila Bala, Los Angeles Times | 10.21.2024

Turmoil at 23andMe, a company offering popular at-home DNA testing, has upset the industry. Following the resignation of every independent...

DNA on Money
By Maggie Harrison Dupré, Futurism [cites CGS' Katie Hasson] | 10.19.2024

A US-based startup called Heliospect Genomics is charging parents tens of thousands of dollars to "screen" embryos they conceive for...

gene therapy graphic
By Fyodor Urnov, The CRIPSR Journal | 10.18.2024

The field of clinical gene editing has a bona fide crisis on its hands—a crisis that has to, and can...

tasmanian tiger
By Isaac Schultz, Gizmodo | 10.18.2024

Colossal Biosciences, a company mainly known for intending to genetically engineer proxies for several iconic extinct species, announced this week...